Clearing melanoma with immunotherapy after surgery
Part of Cancer, Skin clinical trials.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with high-risk melanoma (stage 2B, 2C, 3A, 3B, 3C, 3D, or fully resected stage 4)
- You have had surgery to remove all visible cancer, and scans show no cancer left
- You are able to start immunotherapy after surgery
- You have not received any prior cancer treatment for melanoma, including immunotherapy drugs like nivolumab or relatlimab
- You agree to use effective birth control during and for 6 months after treatment (if applicable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests if giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can improve outcomes for patients with stage III melanoma that can be removed. It is for people who have not had certain treatments recently or whose melanoma is not in the eye.
This trial tests immunotherapy given before surgery to help shrink or control stage III melanoma that has spread to nearby areas (lymph nodes/region). If it works, it may improve outcomes after the melanoma is removed.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
Hear when a new Cutaneous Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.